Endpoints NewsOriginal article
#EADV26: Merck shows off mid-stage win for Prometheus drug in skin condition
Phase 2positivetulisokibartPositive
AI Analysis
Summary
Merck presented positive mid-stage data for tulisokibart, a dermatology drug acquired through its $10.8 billion Prometheus Biosciences acquisition, with both middle and high doses achieving statistically significant results in a skin condition.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Both middle and high doses achieved statistically significant results
Importance:6/10
Sentiment:
0.70
Phase 2 datadermatologyacquisition
Related Companies
Read the original article
Published by Endpoints News on September 30, 2026 5:00 AM